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Abstract: Anesthetic and anti-epileptic drugs used in pediatric and obstetric medicine and 
several drugs, including alcohol, that are abused by pregnant women, trigger widespread 
neuroapoptosis in the developing brain of several animal species, including non-human 
primates. Caffeine (CAF) is often administered to premature infants to stimulate 
respiration, and these infants are also exposed simultaneously to anesthetic drugs for 
procedural sedation and/or surgical procedures. Pregnant women who abuse alcohol or 
other apoptogenic drugs also may heavily consume CAF. We administered CAF to infant 
mice alone or in combination with alcohol, phencyclidine, diazepam, midazolam, 
ketamine, or isoflurane, which are drugs of abuse and/or drugs frequently used in pediatric 
medicine, and found that CAF weakly triggers neuroapoptosis by itself and markedly 
potentiates the neuroapoptogenic action of each of these other drugs. Exposure of infant 
mice to CAF + phencyclidine resulted in long-term impairment in behavioral domains 
relevant to attention deficit/hyperactivity disorder, whereas exposure to CAF + diazepam 
resulted in long-term learning/memory impairment. At doses used in these experiments, 
these behavioral impairments either did not occur or were substantially less pronounced in 
mice exposed to CAF alone or to phencyclidine or diazepam alone. CAF currently enjoys 
the reputation of being highly beneficial and safe for use in neonatal medicine. Our data 
suggest the need to consider whether CAF may have harmful as well as beneficial effects 
on the developing brain, and the need for research aimed at understanding the full 
advantage of its beneficial effects while avoiding its potentially harmful effects. 
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1. Introduction 
Acute exposure of the developing animal brain to several classes of drugs, including those that 
block NMDA glutamate receptors, those that activate GABAA receptors, and alcohol (which has both 
NMDA antagonist and GABA-mimetic properties), triggers widespread apoptotic death of neurons [1–27]. 
Numerous animal species, including non-human primates [28–40] are susceptible. Early exposure to 
these agents is associated with long-term neurobehavioral disturbances in both rodents [6,25,41–45] 
and non-human primates [37]. The window of peak vulnerability coincides with the developmental 
period of rapid synaptogenesis [1,2], also known as the brain growth spurt period, which in mice and 
rats occurs primarily during the first 2 weeks after birth, but in humans extends from about mid-gestation 
to several years after birth [46].  
Included among agents that have neuroapoptogenic activity are some that may be abused by 
pregnant mothers [alcohol, phencyclidine (PCP), ketamine, barbiturates, benzodiazepines], and many 
that are used in obstetric and pediatric medicine. Of major concern are alcohol and pediatric drugs in 
the sedative-anesthetic and anti-epileptic categories, because millions of human fetuses or infants are 
exposed to these agents every year throughout the world. Evidence implicating agents in these 
categories as human neuropathogens includes the following: (1) Exposure of the human fetus to 
alcohol is well known to cause neuropathological changes in the developing brain and long-term 
neurobehavioral disturbances (termed fetal alcohol spectrum disorders, FASD) [47–49]; (2) Results of 
recent multicenter studies [50–52] indicates that children who were exposed in utero to the anti-epileptic 
drug (AED), valproate, during the third trimester of pregnancy have a 9–12 point deficit in IQ, and 
third trimester exposure to other AEDs (carbamazepine, lamotrigine, phenytoin) was associated with 
significant impairment in verbal communication skills; (3) Several recently reported studies [53–59] 
by independent research groups document that exposure of human infants to brief anesthesia 
significantly increases risk for long-term neurocognitive impairment in domains relevant to attention 
deficit/hyperactivity disorder (AD/HD) and/or a learning disability. 
Pre-term infants are often exposed to multiple drugs in the neonatal intensive care unit (NICU), and 
the interactions between these agents have not been adequately studied. Because premature infants 
have frequent and repeated apnea and bradycardia spells, it is common practice to administer CAF to 
these infants in high doses to stimulate respiration and prevent spells of apnea [60,61]. When used in 
this context, CAF is considered safe and highly beneficial [62,63]. In fact, there is evidence that CAF 
can protect against hypoxia-induced brain damage in infant rats [64], and may reduce the incidence of 
cerebral palsy when administered to premature human infants [65]. However, there is also evidence 
that in the infant animal brain CAF may have neurotoxic properties. Kang et al. [66] reported that 
administration of CAF to 7 day old rats (50 mg/kg every 8 h × 3 = a total dose of 150 mg/kg) caused 
apoptotic neurodegeneration in several brain regions. Evidence that CAF is protective against  
hypoxia-induced brain damage, but can promote apoptotic neurodegeneration is not necessarily 
contradictory, in that hypoxic brain damage is mediated by an excitotoxic mechanism, and it has been 
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demonstrated that excitotoxic and apoptotic neurodegeneration are two separate and distinct forms of 
cell death [67].  
Premature infants who are exposed to high doses of CAF to stimulate respiration are also frequently 
exposed to sedative/anesthetic drugs (procedural sedation) on a repetitive or continuous basis, 
sometimes for days or weeks. They also may be exposed acutely to deep anesthesia for surgical 
procedures, in which case CAF is sometimes co-administered to counteract anesthesia-induced 
respiratory depression [60]. It is not known how CAF may interact with these anesthetic drugs at a 
cellular level in the developing brain, or whether such interaction is beneficial or detrimental. 
However, if CAF has pro-apoptotic properties [66], administering it together with anesthetic drugs that 
also have pro-apoptotic properties could hypothetically be detrimental. To test this hypothesis, we 
administered CAF alone or together with various drugs that have known apoptogenic properties to 
infant mice, and examined the brains several hours later for evidence of acute neuroapoptosis. We also 
conducted experiments aimed at determining how it may influence long-term neurobehavioral 
outcome, if infant mice exposed to an NMDA antagonist or a GABA agonist drug are also exposed 
simultaneously to CAF.  
2. Experimental Procedures 
2.1. Subjects 
All animal procedures were conducted in accordance with guidelines developed by the National 
Academy of Science and were approved by the Washington University Animal Care Committee. All of 
the subjects for these experiments were 4 day old (P4) ICR white mice.  
2.2. Blood CAF Levels 
In planning these experiments, we first sought to determine what dose(s) of CAF should be 
administered to infant mice in order to induce clinically relevant CAF blood levels. In pediatric 
medicine blood levels of CAF in the range of 6 to 50 μg/mL are considered safe and therapeutic for 
premature infants [62]. Blood levels on the high side of this dose range have been documented due to 
extremely heavy consumption of CAF in pregnancy [68]. The phenomenon under study is an acute 
reaction—drug-induced developmental neuroapoptosis—that is triggered by a single dose of the 
apoptogenic agent. In the pediatric NICU, CAF is administered semi-chronically over a period of days 
or weeks. An initial bolus dose is given which causes high blood levels acutely that taper gradually and 
are supplemented by daily maintenance doses to keep the blood concentration at a desired steady-state 
level. In pilot experiments, we attempted to simulate the acute phase of this type of treatment regimen 
by administering a single subcutaneous (sc) dose of CAF (free base, Sigma-Aldrich Inc., St. Louis, 
MO, USA) to 4 day old infant mice at 40 or 80 mg/kg and found that this produced blood CAF levels 
at 6, 12 and 24 h of 12, 8.9, 2.7 or 65, 43 and 15 μg/mL, respectively. The mean CAF blood level over a 
24 h period for 40 and 80 mg/kg doses was 7.4 and 38 μg/mL, respectively. Since these values are 
within the range (6–50 μg/mL) considered safe for premature human infants [62], we elected to use  
40 and 80 mg/kg as our low and high doses respectively.  
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2.3. Individual Experiments 
2.3.1. Experiment #1—Apoptogenic Action of CAF + Alcohol 
In our first experiment, P4 mice (n ≥ 6 per group) were treated with saline (control group), or CAF 
(40 or 80 mg/kg), or alcohol (2.5 g/kg), or with CAF + alcohol at the same doses of CAF and alcohol. 
Six hours following drug administration all pups were deeply anesthetized, perfused with fixative  
(4% paraformaldehyde in Tris buffer), and their brains prepared for histological evaluation by methods 
described below. The dose of alcohol used in this experiment is quite low compared to doses in the 
range of 5 g/kg typically used by fetal alcohol researchers to study the toxic effects of alcohol on the 
developing brain [69]. The doses of CAF used are lower than those used by Kang et al. [66] in their 
original demonstration that CAF has apoptogenic properties. As indicated above, at 40 mg/kg and  
80 mg/kg, CAF produces blood levels in the infant mouse that are in the low range and high range, 
respectively, of blood levels considered safe and therapeutic for human premature infants [62]. 
2.3.2. Experiment #2—Apoptogenic Action of CAF + NMDA antagonists 
Alcohol has both NMDA antagonist and GABAmimetic properties, so next we tested the effects of 
CAF in combination with drugs that have only NMDA antagonist or only GABAmimetic (see  
Section 2.3.3 below) properties. For the NMDA antagonist experiments we elected to study two agents, 
phencyclidine (PCP) and ketamine. Both of these NMDA antagonists have anesthetic properties and 
are sometimes abused by pregnant women. Many decades ago, PCP was approved by FDA as a 
dissociative anesthetic for use in human medicine, but it was soon withdrawn because of powerful 
psychotomimetic side effects. PCP is currently recognized as a drug of abuse (Angel Dust) that 
frequently causes acute schizophrenia-like psychotic reactions and also can trigger violent behaviors. 
Ketamine is a structural analog of PCP which has similar but milder side effects and is frequently used 
in pediatric medicine for induction of anesthesia, or as a procedural sedative. For the PCP experiments, 
P4 infant mice (n ≥ 6 per group) were treated subcutaneously with saline (control group), or CAF  
(80 mg/kg), or PCP (25 mg/kg), or with CAF + PCP at the same doses. For the ketamine experiments, 
P4 infant mice (n ≥ 6 per group) were treated subcutaneously with saline (control group), or CAF  
(80 mg/kg), or ketamine (40 mg/kg at time zero and 30 mg/kg 2 h later, or CAF + ketamine at the 
same doses. The doses of both PCP and ketamine are sub-anesthetic but deeply sedating. Ketamine 
was administered as an initial bolus followed by a subsequent maintenance dose because it has a short  
half-life. Six hours following drug administration all pups were deeply anesthetized, perfused with 
fixative (4% paraformaldehyde in Tris buffer), and their brains prepared for histological evaluation by 
methods described below. 
2.3.3. Experiment #3—Apoptogenic Action of CAF + GABAmimetics 
To test the apoptogenic action of CAF + GABAmimetic agents, we chose diazepam and isoflurane. 
Diazepam is a prototypic member of the benzodiazepine class that acts at GABAA receptors to enhance 
the inhibitory action of GABA. Benzodiazepines are the agents most frequently used in neonatal 
intensive care units for procedural sedation to keep infants in a state of reduced awareness, reduced 
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sensitivity to pain, and reduced motor activity while diagnostic or therapeutic procedures are being 
performed. Diazepam is also used in pediatric medicine as an antiepileptic to arrest seizure activity, 
and is an anxiolytic drug that is sometimes abused by pregnant women. Human infants sometimes 
require surgery for life threatening conditions and, therefore, must be exposed acutely to anesthetic 
drugs at doses sufficient to render them unconscious and insentient to pain. Diazepam may be used for 
induction, and then isoflurane, or a similar halogenated ether (sevoflurane, desflurane), is routinely 
used to maintain a deep surgical plane of anesthesia for major surgical procedures lasting several or 
more hours. The anesthetic action of isoflurane is thought to be due primarily to an action at GABAA 
receptors, although it may act by other mechanisms as well. 
For the diazepam experiments, P4 infant mice (n ≥ 6 per group) were treated subcutaneously with 
saline (control group), or CAF (80 mg/kg), or diazepam (10 mg/kg) or with CAF + diazepam at the 
same doses. This dose of diazepam is sub-anesthetic but heavily sedating for the infant mouse. For the 
isoflurane experiments, P4 infant mice (n ≥ 6 per group) were exposed to saline in room air (control 
group), or CAF (80 mg/kg), or to isoflurane (2% concentration × 2 h duration), or to CAF + isoflurane. 
The concentration of isoflurane required to fully anesthetize an infant mouse is 2.7% [70], but this 
concentration suppresses respiration severely and causes a high mortality rate if respiratory support 
procedures are not being employed. Because of the small size of infant mice it is not feasible to 
intubate them or perform effective respiratory control procedures. To work around this problem, we 
limited the duration of anesthesia to 2 h, and the concentration of isoflurane to 2%, which provides 
moderate but not full anesthesia. Six hours following administration of drugs or saline, all pups were 
deeply anesthetized, perfused with fixative (4% paraformaldehyde in Tris buffer), and their brains 
prepared for histological evaluation by methods described below. 
2.3.4. Experiment #4—Long-Term Neurobehavioral Effects of CAF + NMDA antagonist or GABAmimetic  
In light of recent evidence that brief exposure of human infants to general anesthesia is associated 
with increased risk for long-term neurocognitive disturbances [53–59] we conducted an experiment 
aimed at determining whether CAF can increase the potential of an NMDA antagonist or GABAmimetic 
drug to cause long-term neurobehavioral disturbances. For these experiments, we subjected P4 infant 
mice (n ≥ 10 per group) to treatment with PCP (10 mg/kg) or diazepam (10 mg/kg), either with or 
without co-administration of CAF. We originally intended to use the same dose of PCP (25 mg/kg) 
that was used in Section 2.3.2 above, but we found that mouse pups are very slow in recovering from 
this dose and this caused a high rate of maternal neglect and/or cannibalism. Therefore, a lower dose 
was used for these long-term neurobehavioral studies. Following treatment with saline, CAF, PCP, 
diazepam, or CAF + PCP or CAF + diazepam, the pups were kept warm in individual boxes containing 
bedding from the maternal nest for several hours until they recovered from anesthesia, then were 
returned to the maternal nest for long-term survival and neurobehavioral testing. At 21 days of age, 
pups were weaned and group-housed for behavioral testing beginning at P23. All mice were given a 
battery of sensorimotor tests to evaluate effects of the drug treatment on any aspects of balance, 
coordination or strength that may influence performance on the behavioral tests. Reactivity and 
habituation to handling for each animal was evaluated over 3 days by three independent raters using a 
scale from 1 to 5, with 1 being little or no movement and 5 being extreme reactivity including biting 
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the handler or vocalization. Locomotor activity, rearing and exploratory behavior was assessed in activity 
chambers (Hamilton-Kinder) between P26 and P28. Learning and memory performance was measured 
from P28 to P45 using cued, place and probe versions of the Morris Water Maze similar to previously 
described methods [45]. The resident-intruder test was used to measure aggressive behaviors in adult 
male mice from P50 to P60. Male mice were individually housed for 1 week prior to testing and 
bedding was not changed for 3 days before introduction of the intruder mouse. Unfamiliar male 
C57/BL6 mice of the same age were used as intruders. A different, unfamiliar mouse was placed in the 
home cage of the test mouse on 3 consecutive days, and interactions were recorded and scored for a  
10 min period using Stopwatch software (Emory University, GA, USA). Frequency, duration and 
latency for fighting, biting, pawing, following and alone time were scored for each session.  
Statistical analyses of the behavioral data were conducted using analysis of variance models 
(ANOVA), one-way ANOVA for sensorimotor and resident-intruder tests and Repeated Measures 
ANOVA for activity, learning and memory, reactivity to handling tests. Bonferroni correction was 
used for all post hoc comparisons (Statistica, StatSoft, Inc., Tulsa, OK, USA).  
2.4. Histopathology 
In the original studies characterizing the apoptogenic properties of alcohol and anesthetic drugs [1–12], 
the cell death process was documented by TUNEL staining (non-specific marker for apoptosis), 
DeOlmos cupric silver staining (marker for cell death) and immunohistochemical staining for activated 
caspase 3 (AC3), a relatively specific marker for apoptosis. In addition, a detailed electron microscopic 
evaluation [1,2,4,6,7,10,12] revealed that the dying cells displayed all of the classical ultrastructural 
changes characteristic of apoptotic cell death, as originally described by Wyllie et al. [71]. In studies 
examining gene-regulated biochemical pathways, it was found that the cell death process involves 
translocation of Bax protein to mitochondrial membranes where it disrupts membrane permeability, 
allowing extra-mitochondrial leakage of cytochrome c, followed by a sequence of changes culminating 
in activation of caspase-3 [15,20,21]. Commitment to cell death occurs prior to the AC3 step [21]; 
therefore, immunohistochemical detection of neurons positive for AC3 has become recognized as a 
reliable means of mapping and quantifying dying cells that have already progressed beyond the point 
of cell death commitment. An additional feature of AC3 making it the method of choice for studying 
this cell death process is that in the early stages of cell death it stains the entire cell body and its 
processes, which facilitates identification of cell type, and in more advanced stages it reveals 
degenerative morphological changes (shrinkage, fragmentation, condensation) which allows one to 
trace the steps in the degenerative process.  
For the above reasons, AC3 immunohistochemistry was chosen as the method for mapping and 
quantifying the cell death process in the present study. Six hours after initiation of drug exposure, the 
pups were deeply anesthetized with pentobarbital and perfused with fixative (4% paraformaldehyde in 
Tris buffer) through the left cardiac ventricle and ascending aorta. The brains were removed from the 
skull and immersed in the perfusion fixative overnight in the refrigerator, then serially sectioned by 
vibratome in the sagittal plane and stained immunohistochemically for activated caspase-3 (AC3) by 
methods previously described [20,21]. Briefly, vibratome sections (70 µm thick) were washed in  
0.01 M phosphate-buffered saline (PBS), quenched for 10 min in a solution of methanol containing 3% 
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hydrogen peroxide, then incubated for 1 h in blocking solution (2% BSA/0.2% milk/0.1% Triton X-100 
in PBS), followed by incubation overnight in rabbit anti-active caspase-3 antiserum (D175, Cell 
Signaling Technology, Beverly, MA, USA) diluted 1:1000 in blocking solution. Following incubation 
with D175 primary antibody, the sections were incubated for 1 h in secondary antibody (goat anti-rabbit 
1:200 in blocking solution), and then reacted in the dark with ABC reagents (standard Vectastain ABC 
Elite Kit, Vector Labs, Burlingame, CA, USA) for 1 h. The sections were then washed 3 times with 
PBS, and incubated with VIP reagent (Vector VIP substrate kit for peroxidase, Vector Labs, 
Burlingame, CA, USA) to develop a purple color. 
2.5. Quantitative Cell Counts 
AC3-stained sagittal sections chosen at 0.5 mm intervals from the midline to lateral edge of the 
hemi-brain were imaged and quantitatively evaluated with the help of a stereology system consisting 
of the following components: Stereo Investigator (MicroBrightField, Inc., Colchester, VT, USA) on a 
Pentium III PC, connected to a Prior Optiscan motorized stage (ES103 XYZ system, Prior Scientific 
Inc., Rockland, MA, USA) mounted on a Nikon Labophot-2 microscope. The boundaries of each 
section were traced into the PC and from the tracings Stereo Investigator calculated the area in each 
section. AC3-positive neurons with visible processes were all counted. The population estimator 
function of Stereo Investigator was used to mark each profile while it was counted to ensure that no 
profile would be missed or counted twice. The counts from each section of a given brain were summed 
and divided by the tissue volume (total area times thickness of the sections) from which the counts 
were obtained to yield an estimate of the density of AC3-positive profiles (number per mm3). The counts 
were performed in a blinded manner in which the treatment condition was unknown to the person 
doing the counting.  
2.6. Statistical Methods 
Statistical analysis of the neuroapoptosis density count data was performed by ANOVA followed 
by post hoc Bonferroni multiple comparisons test, using Prism 4.0b software (GraphPad Software Inc., 
San Diego, CA, USA). All data are expressed as Mean ± S.E.M. The probability level for significance 
was set at p < 0.05. 
3. Results 
3.1. Apoptogenic Action of CAF + Alcohol 
CAF was administered to P4 infant mice at 40 or 80 mg/kg, and alcohol at 2.5 g/kg, either alone or 
together with each dose of CAF. The density of apoptotic profiles for each treatment group in the  
40 mg/kg CAF experiment is given in Figure 1A and for the 80 mg/kg CAF experiment in Figure 1B. 
The profile counts for the control group represent the natural rate of neuroapoptosis in the developing 
mouse brain at this age. The apoptosis counts for the alcohol group in each experiment were 
significantly increased, and the counts for CAF at the higher dose were increased to a moderate degree, 
but at the lower dose were not different from the controls. Surprisingly, each dose of CAF, when 
combined with alcohol, resulted in a much larger increase in neuroapoptosis than could have been 
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predicted by the observed response to CAF alone; the amount of increase was so great that it suggests 
that a supra-additive (potentiating) mechanism may be operative. 
Figure 1. Apoptogenic action of caffeine (CAF) alone or in combination with alcohol. 
Apoptotic profiles were detected by activated caspase 3 (AC3) immunohistochemical 
staining. (A) Although CAF at 40 mg/kg (CAF-40) caused no increase in apoptosis, when 
this dose was combined with alcohol, the apoptotic response to alcohol was markedly 
increased. (B) CAF at 80 mg/kg (CAF-80) caused a modest but significant increase in cell 
death, and when this dose of CAF was combined with alcohol the apoptotic response was 
dramatically increased.  
 
3.2. Apoptogenic Action of CAF + NMDA Antagonists (PCP or Ketamine) 
CAF was administered to P4 infant mice at 80 mg/kg, and PCP and ketamine were administered at 
sub-anesthetic doses either alone or in combination with CAF. In Figure 2A,B, apoptosis counts show 
that both CAF alone and PCP or ketamine alone caused a modest but significant neuroapoptosis 
response, and when CAF was combined with either drug, there was a much more robust response than 
could have been predicted by the responses to the individual agents. This indicates that CAF augments 
neuroapoptosis induced by either of two NMDA antagonist drugs, and the degree of augmentation is in 
the supra-additive range. 
Figure 2. Apoptogenic action of CAF in combination with phencyclidine (PCP) (A) or Ketamine (B). 
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3.3. Apoptogenic Action of CAF + GABAmimetics (Diazepam or Isoflurane)  
For the diazepam experiments, CAF was administered at 80 mg/kg and diazepam at 10 mg/kg to P4 
infant mice. The histogram in Figure 3A reveals that the neuroapoptosis counts in CAF or diazepam 
treated mice were significantly increased to a moderate degree and were increased to a much greater 
degree following CAF + diazepam exposure. 
For the isoflurane experiments, CAF was administered at 80 mg/kg and isoflurane was administered 
as a gas for 2 h at 2% concentration. Because of the respiratory depressant effects of isoflurane and the 
respiratory stimulatory effects of CAF, this experiment provided an opportunity to observe the 
interactive effects of these agents on respiration as well as their interactive effects on neuroapoptosis 
outcome. Exposure of P4 pups to isoflurane alone for 2 h induced respiratory insufficiency in all pups, 
resulting in dyspnea, cyanosis and 15% mortality. In contrast, there was zero mortality in the control, 
CAF alone or CAF + isoflurane groups, and none of these groups showed signs of respiratory 
insufficiency. This signifies that CAF effectively counteracted both the respiratory depressant action of 
isoflurane and its lethal consequences. The histogram in Figure 3B shows that both CAF and 
isoflurane increased the neuroapoptosis rate to a moderate but significant degree, and adding CAF to 
isoflurane resulted in a much greater increase which, like the response to CAF + alcohol or NMDA 
antagonists, was in a supra-additive range. It is noteworthy that although the isoflurane group 
experienced significant hypoxia, which might be expected to increase the cell death count, and the 
CAF + isoflurane group did not experience hypoxia, the exaggerated cell death response was in the 
CAF + isoflurane group that did not experience hypoxia.  
Figure 3. Apoptogenic action of CAF in combination with diazepam (A) or isoflurane (B). 
 
3.4. Overview of CAF’s Pro-Apoptotic Action 
The doses selected for each of the primary apoptogens in this study (alcohol, PCP, ketamine, 
diazepam, isoflurane) were sedating but sub-anesthetic doses that induced a relatively mild 
neuroapoptosis reaction, and the dose of CAF was one that caused only a relatively mild 
neuroapoptosis reaction. Consistently, combining CAF with any of these primary apoptogens resulted 
in a more robust neuroapoptosis response than would have been predicted by the modest responses to 
the individual agents. In order to provide an overview of CAF’s pro-apoptotic activity in relation to 
primary apoptogens as a like-acting group of neurotoxic agents, we developed a single composite data 
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set containing the apoptosis density counts for all animals exposed to a primary apoptogen (n = 39), a 
second composite set for all animals exposed to 80 mg/kg CAF (CAF-80) (n = 32), a third for all 
control animals (n = 37), and a fourth for all exposed to CAF-80 + an apoptogen (n = 37). The 
histogram in Figure 4A illustrates these composite data. Statistical evaluation by ANOVA revealed a 
main treatment effect [F(3, 136) = 64.00, P < 0.001]. By Bonferroni post hoc analysis, the mean 
density count for both the composite apoptogens group and the CAF-80 group was significantly 
increased compared to the composite control group (P < 0.001), and the composite apoptogens group 
was significantly greater than the Caf-80 group (P < 0.01). The density count for the composite  
CAF-80 + apoptogens group was significantly increased (P < 0.001) compared to each of the other 
three groups. In Figure 4B the composite data for each treatment group have been adjusted to reflect 
only the density counts attributable to drug treatment (control values representing natural apoptosis 
subtracted), and this reveals that by an additive mechanism the composite CAF-80 group would add 
266.27 profiles/mm3 to the composite apoptogens group (dashed line in Figure 4B), but the amount 
actually added was 1200.98 profiles/mm3 (4.5 times the expected amount). This supports the 
interpretation that CAF exerts a supra-additive pro-apoptotic action when combined with any of 
several apoptogenic agents. 
 
Figure 4. Overview of CAF’s pro-apoptotic action. (A) The apoptotic profile count for the 
composite CAF-80 group and for the composite apoptogens group were both significantly 
increased compared to the composite control group, and the CAF-80 + apoptogens group was 
increased significantly and to an extreme degree compared to any of the other three groups.  
(B) The data in A are displayed here with the control values (natural apoptosis) subtracted out 
so that the remaining values reflect only the amount of cell death attributable to the drug 
exposures. Adding the bar for CAF-80 to the bar for the apoptogens group would yield a value 
represented by the dashed line. But the actual value for CAF-80 + apoptogens group was much 
greater, signifying that CAF acts by a supra-additive mechanism.  
 
 
3.5. Regional and Cellular Distribution of CAF’s Pro-Apoptotic Action 
The regional distribution of apoptotic neurodegeneration induced by NMDA antagonist and 
GABAmimetic drugs depends on the developmental age at the time of drug exposure. At a given age, 
both classes of drugs, with some exceptions, tend to affect the same brain regions, although not 
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necessarily the same cell types within a given region. The regions typically affected most severely in 
the P4 infant mouse are the cerebellum, inferior and superior colliculi, caudate-putamen, many 
thalamic nuclei, retrosplenial cortex, subiculum and hippocampal formation and all major divisions of 
the neocortex. The apoptotic profile counts reported herein are given as mean density/mm3 across all 
of these brain regions. The histological appearance of the acute neurodegenerative reaction, as detected 
by AC3 staining, is depicted for whole brain sagittal sections in Figure 5 and for individual brain 
regions in Figure 6 (neocortex), Figure 7 (thalamus) and Figure 8 (cerebellum). These illustrations 
support the interpretation that CAF tends to augment the cell death reaction induced by various 
primary apoptogens in each of the brain regions where they are typically most active. 
Figure 5. Regional Patterns of Neuroapoptosis. All panels are stained by activated caspase 3 
(AC3) immunohistochemistry. In the control brain the AC3-positive profiles (dark specks) 
are distributed in a relatively sparse and random pattern over many brain regions. In the 
brains exposed to caffeine, PCP, diazepam (Diaz) or isoflurane (Iso), the density of  
AC3-positive profiles is moderately increased, especially in neocortex, hippocampus (HC), 
subiculum (SUB), retrosplenial cortex (RSC), Caudate (CAUD), Thalamus (THAL), 
colliculi and cerebellum. In the brains exposed to caffeine + PCP, diazepam or isoflurane 
the density of apoptotic profiles is markedly increased in each of these same regions. 
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Figure 6. Neuroapoptosis in the Neocortex. These detail views reveal that combining 
caffeine with PCP, diazepam or isoflurane causes a marked increase in the density of 
apoptotic profiles in the superficial cortical layers, and also causes spread of the cell death 
reaction to include the deeper cortical layers. 
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Figure 7. Neuroapoptosis in the Thalamus. These detail views focus on the dorsomedial 
thalamic nucleus and neighboring thalamic nuclei. Compared to the control brain, there is a 
substantially higher density of apoptotic profiles in the brains exposed to caffeine, PCP, 
diazepam or isoflurane, and show a low density of apoptotic profiles in the control brain 
and a more striking increase in the brains exposed to caffeine in combination with PCP, 
diazepam or isoflurane.  
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Figure 8. Neuroapoptosis in the cerebellum. These panels illustrate the neuroapoptosis 
response in folium 10 (X) of the infant mouse cerebellum of a control (Cont) brain, 
compare to brains exposed to caffeine (Caf), phencyclidine (PCP), caffeine + PCP (C + P), 
Diazepam (Diaz), caffeine + diazepam (C + D), Isoflurane (Iso) or caffeine + isoflurane  
(C + I). The large dark profiles in curvilinear display are apoptotic Purkinje cells. The 
smaller dark profiles are in a migratory status and are of uncertain identity [4]. 
 
3.6. Long-Term Neurobehavioral Effects of CAF + PCP or Diazepam 
3.6.1. CAF + PCP 
When normal mice are placed in a chamber with which they are not familiar, they typically show 
exploratory behavior, including frequent rearing, sniffing and moving about from one edge of the 
chamber to another. Mice exposed in infancy to saline, CAF, PCP or CAF + PCP were evaluated as 
adolescents for these behaviors when placed in an activity chamber (representing a novel 
environment). The data for frequency of rearing and the amount of time spent in the center of the 
chamber versus at the edges of the chamber are documented in Figure 9. Compared to controls, 
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frequency of rearing was moderately decreased in CAF-exposed mice (non-significant), and was 
decreased to a greater degree in the PCP-exposed group (P < 0.01), and to even a greater degree in the 
CAF + PCP exposed group (P < 0.0006). Time spent in the center of the chamber and away from the 
edges was also increased to an exaggerated degree in CAF + PCP mice compared to all other groups  
(P < 0.0007). Decreased rearing and reduced exploratory behavior are consistent with an attention 
deficit disorder [72], while staying in the center of the chamber and avoidance of the edges is a sign of 
increased emotionality and anxiety.  
Figure 9. Frequency of Rearing and Time Spent at Center versus Edges of Chamber. 
 
Because the PCP and CAF + PCP mice showed signs of irritability and agressiveness, we 
performed a reactivity to handling test and subjected the saline and CAF + PCP males to a resident 
intruder test that measures aggressivity. These results (Figure 10) show that on three successive days 
of testing the PCP, and much more so the CAF + PCP mice, displayed hyper-reactivity to handling 
and, whereas the saline controls became habituated to handling by the 3rd day of testing, the CAF + 
PCP mice failed to habituate. In the resident intruder test, the CAF + PCP mice often attacked and 
initiated fights with other males, whereas the saline control males showed no aggressive tendencies at 
all. The caffeine, PCP and caffeine + PCP mice were also tested on the Morris water maze and showed 
no deficits in learning/memory domains (data not shown). 
Figure 10. Reactivity to Handling and Male Aggression. 
 
3.6.2. CAF + Diazepam 
In diazepam-treated mice, adding CAF did not result in significant differences in measures of 
reactivity to handling or open field activity, but did impair learning. In the Morris Water Maze there 
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were no differences between groups in swim speeds or cued trials, but distance traveled and latency to 
find the platform were significantly increased in diazepam + CAF mice and this group showed no 
evidence of learning across the 5 days of testing (Figure 11). 
Figure 11. Latency Scores: Morris Water Maze. 
 
4. Discussion 
CAF enjoys the reputation of being a highly beneficial drug for use in neonatal medicine. By 
blocking adenosine receptors, CAF is believed to increase the release of glutamate at excitatory 
receptors and, therefore, is used to stimulate respiration in premature infants who are apnea-prone due 
to weakness of the respiratory reflex. Among the benefits recently attributed to CAF therapy for 
premature infants is decreased morbidity associated with bronchopulmonary dysplasia and cerebral 
palsy [65]. In addition to these potential benefits, neonatologists currently consider CAF so safe that 
they are questioning the need for monitoring CAF blood levels when administering it semi-chronically 
to premature infants [62,63,73]. 
The present study was a proof of concept study designed to determine whether CAF has pro-apoptotic 
properties in the developing brain, which might cause it to interact unfavorably with other drugs that 
have pro-apoptotic properties. Our findings document that CAF does have pro-apoptotic actions in the 
developing brain, and when administered in combination with other agents that have neuroapoptogenic 
properties it can cause a striking potentiation of their apoptogenic activity. Thus, notwithstanding 
CAF’s potential benefits, our data suggest that it may also, under certain circumstances, be harmful for 
the developing brain. The two human settings in which substantial CAF exposure occurs and might 
potentially be harmful are: (1) A drug abuse setting in which a pregnant mother drinks coffee or other 
CAF-containing beverages or foods while abusing drugs that have apoptogenic properties (e.g., alcohol, 
PCP, ketamine, benzodiazepines or barbiturates). (2) A medical setting in which CAF is administered 
to premature infants as a respiratory stimulant when these infants are also being exposed to 
sedative/anesthetic drugs. In the following paragraphs, we will discuss risk associated with CAF 
exposure in each of these settings. 
Drug Abuse Setting: Our findings indicate that CAF has the potential to increase the neurotoxicity 
of several drugs of abuse (DOA), including those that act at NMDA receptors, those that act at GABA 
receptors, and alcohol, which interacts with both of these receptor systems. To further assess the 
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human relevance of these findings it will be necessary to conduct dose/response testing to determine 
threshold doses of CAF and each DOA for triggering a potentiated apoptotic response. In the absence 
of such data, it is unclear whether CAF at doses typically ingested by pregnant women in combination 
with apoptogenic DOA at doses in the abuse range would trigger a potentiated neuroapoptosis reaction. 
Risk would presumably be greatest for CAF in combination with alcohol, because millions of fetuses 
annually throughout the world are exposed to alcohol, sometimes under binge conditions [74,75], and a 
high percentage of those fetuses are likely to be exposed simultaneously to CAF, given the high 
frequency with which CAF is used and abused in modern societies [76]. Factors to consider in evaluating 
risk posed by CAF/alcohol exposures are as follows: (1) A single exposure to alcohol, triggers 
widespread neuroapoptosis in the developing brain of infant rodents [2,7] or fetal monkeys [35,36];  
(2) Binge drinking [75], even on a single occasion [74] during pregnancy, is associated with long-term 
neurobehavioral disturbances in the offspring; (3) Pregnant mothers with a strong alcohol and strong 
CAF habit may expose their fetuses to binge amounts of alcohol [74,75] and repetitive boluses of CAF 
intake [77] throughout a given day, and on multiple occasions during a given pregnancy; (4) During 
the last trimester of pregnancy, the half-life for CAF in maternal blood is 2–3 times greater than in the 
non-pregnant state [78]; (5) Even in the non-pregnant state, alcohol inhibits the liver enzyme system 
that catalyzes the metabolism of CAF, thereby prolonging its half life [79].  
We studied the long-term neurobehavioral effects of CAF in combination with the NMDA 
antagonist DOA, PCP, and found that both CAF and PCP caused an increase in AD/HD-like behaviors, 
and the two drugs in combination caused a more pronounced AD/HD-like syndrome. This suggests a 
special relationship between CAF, the NMDA receptor system and AD/HD-like behavioral disorders, 
which is consistent with other prior reports [80,81], including the observations of Fredriksson et al. [41] 
who found that treatment of 10 day old rats with ketamine (NMDA antagonist DOA and widely used 
general anesthetic) caused long-term AD/HD-like behavioral disturbances. We also assessed the  
long-term neurobehavioral effects of CAF in combination with the GABA agonist, diazepam, and 
found that the CAF/diazepam combination caused learning/memory impairment. There was no  
cross-over between the diazepam-linked and PCP-linked syndromes in that CAF/diazepam did not 
cause AD/HD-like disturbances, and CAF/PCP did not cause learning impairment. It will be of interest 
to study this phenomenon further with an aim toward establishing correlations between patterns of 
neuronal losses caused by a given drug combination, and neurobehavioral outcomes associated with 
that drug combination. It will also be of interest to do additional testing to determine whether other 
NMDA antagonists, in combination with CAF, preferentially cause AD/HD-like behavioral syndromes, 
and other GABA agonists, in combination with CAF, preferentially cause learning disability syndromes.  
Medical setting: CAF exposure of premature infants is potentially of concern because the duration 
of exposure is typically quite prolonged (continuous for days or weeks), and the doses of CAF used are 
sometimes quite high, based on the current belief that CAF is safe for premature infants even at high 
doses [62]. The doses of CAF used in our experiments produce blood CAF levels in the infant mouse 
that are in the same range as those considered safe for human premature infants. The doses of sedatives 
or anesthetics used in our experiments are doses required for the degree of sedation that human 
premature infants experience when they are subjected to procedural sedation or surgical anesthesia, 
except that procedural sedation sometimes involves continuous or repeated exposure over a period of 
days or weeks, and in our study mice were exposed on only a single occasion. While extrapolation 
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from rodents to humans is always fraught with uncertainties, the original evidence documenting 
apoptogenicity of sedative and anesthetic drugs [1–3,6] was generated in infant rodents, then was 
reproduced in infant and fetal non-human primates [28–35,37–40], and there now are seven recently 
published studies [53–59] documenting that brief exposure of human infants to anesthesia is associated 
with increased risk for long-term neurobehavioral disturbances, including disturbances relevant to both 
AD/HD and learning disability domains. While some of the studies [55–57] have been interpreted as 
evidence that it may require multiple exposures or a total exposure duration ≥2 h for a significant 
neurocognitive disability effect, other studies [53,54,58,59] support the interpretation that a single 
exposure to anesthesia for less than 2 h is sufficient to increase the risk for neurocognitive impairment. 
Collectively, these recent developments suggest that, for this type of toxic mechanism, rodent data may 
be reliable predictors of human risk. 
It may seem like a contradiction that CAF could promote widespread apoptotic cell death 
throughout the brain and also be protective against cerebral palsy. However, these are not mutually 
exclusive possibilities. Protection against cerebral palsy can be explained by CAF preventing apnea 
and hypoxia which, if extreme, can cause pathological accumulation of glutamate at excitatory 
receptors, leading to excitotoxic neurodegeneration, whereas potentiation of anesthesia-induced 
neuroapoptosis is due to the inherent pro-apoptotic property of CAF (mechanism unknown), and a 
comparative analysis of excitotoxic versus apoptotic cell death reveals that these are two separate and 
distinct forms of cell death [12,67]. In fact, excitotoxic neurodegeneration in the infant rodent brain is 
triggered by excessive activation of NMDA receptors [82,83], and apoptotic neurodegeneration is 
triggered by insufficient activation of NMDA receptors [1,83]. In our present experiments, mice 
exposed to isoflurane alone for 2 h experienced a severe and potentially lethal degree of cerebral 
hypoxia. Interestingly, these isoflurane-exposed mice displayed only a moderate degree of 
neurodegeneration, all of which can be explained by the apoptogenic action of isoflurane, and none of 
which had hypoxia-like excitotoxic characteristics. Moreover, adding CAF to the isoflurane protocol 
prevented isoflurane from inducing cerebral hypoxia, while causing it to trigger a much more  
severe neuroapoptosis reaction. This provides cogent new evidence supporting the interpretation that  
hypoxic-ischemic (excitotoxic) neurodegeneration and apoptotic neurodegeneration are two different 
forms of cell death, and factors that promote (or inhibit) excitotoxicity in the developing brain can 
potentially have an opposite effect on apoptogenicity. 
That CAF has pro-apoptotic properties and can induce neuroapoptosis in the developing brain is not 
a novel observation. One decade ago, Kang et al. [66] demonstrated that CAF induces widespread 
apoptotic neurodegeneration in the in vivo infant rat brain, and also induces apoptotic death of cultured 
neurons in vitro. The novel finding that we are adding to the picture is that CAF markedly potentiates 
the neuroapoptogenic action of other drugs, including alcohol and many drugs used widely in pediatric 
and obstetric medicine. We are not aware of any studies on premature infants designed to rule out a 
neurotoxic action of CAF in combination with anesthetic drugs. The widely cited multicenter study by 
Schmidt et al. [65] in which it was reported that CAF is protective against cerebral palsy, used a 
maximum CAF loading dose of 20 mg/kg which is 1/4 as high as the maximal doses that currently are 
being used in some NICUs and are considered safe [62,63,73]. Moreover, in the Schmidt et al. study 
there is no mention of anesthesia exposure for either the group receiving CAF or the group receiving 
placebo. Therefore, it is entirely possible that low blood levels of CAF with minimal anesthesia 
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exposure is protective against cerebral palsy, and high blood levels of CAF with substantial anesthesia 
exposure may be detrimental.  
It is widely recognized that children with a history of premature birth and prolonged care in the 
NICU, have a high incidence of neurocognitive impairment [84], but drugs used in the NICU for 
procedural sedation or to stimulate respiration have, thus far, escaped scrutiny as potential contributory 
factors. Our findings indicate the need for new research aimed at clarifying the degree of risk posed by 
combined exposure of premature infants to CAF and sedative/anesthetic drugs, and a parallel program 
aimed at learning how to take full advantage of CAF’s beneficial effects while avoiding its potentially 
harmful effects. In view of evidence that morbidity associated with cerebral palsy is reduced by CAF 
administration at a low dose [65], a simple measure that might be taken, sooner better than later, would 
be to set limits on the dose of CAF that is used in the NICU. Implementing this recommendation could 
be highly beneficial and is not likely to be detrimental, although clearly it challenges the growing 
belief that CAF is safe for premature infants over a wide range of doses [62,63,73].  
5. Conclusions 
Our data suggest the need to consider whether CAF may have harmful as well as beneficial effects 
on the developing brain, and the need for research aimed at taking advantage of its beneficial effects 
while avoiding its potentially harmful effects. 
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